128
Participants
Start Date
November 29, 2018
Primary Completion Date
September 7, 2021
Study Completion Date
September 7, 2021
LY3454738
Administered IV
LY3454738
Administered SC
Placebo
Administered IV
PAREXEL-Phase 1 Baltimore Harbor Hospital Center, Baltimore
Wake Research Associates, Raleigh
Global Health Research Center, Miami Lakes
Revival Research Corporation, Doral
Palm Beach Research Center, West Palm Beach
Pinnacle Research Group, Anniston
Skin Sciences, PLLC, Louisville
Wright State Physicians Dermatology, Dayton
Detroit Clinical Research Center, Farmington Hills
Arkansas Research Trials, LLC, North Little Rock
Northwest Arkansas Clinical Trials Center, Rogers
Central Sooner Research, Norman
Center for Clinical Studies, Houston
Progressive Clinical Research, San Antonio
California Clinical Trials Medical Group, Glendale
First OC Dermatology, Fountain Valley
Premier Clinical Research, Spokane
ForCare Clinical Research, Tampa
JUVA Skin & Laser Center, New York
Dermatology, Los Prados
GCM Medical Group, PSC - Hato Rey Site, San Juan
Eli Lilly and Company
INDUSTRY